Acne Vulgaris Market 2034

The Acne Vulgaris market report also offers comprehensive insights into the Acne Vulgaris market size, share, Acne Vulgaris epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Acne Vulgaris market size growth forward.

Some of the key highlights from the Acne Vulgaris Market Insights Report:

• Several key pharmaceutical companies, including ddpharma, Arog Pharmaceuticals, Chong Kun Dang Pharmaceutical, Cinclus Pharma, Cogent Biosciences, Daewoong Pharmaceutical, HK inno.N Corporation, Jeil Pharmaceutical, Onconic Therapeutics, Plexxikon, Renexxion, Taiho Pharmaceutical, Takeda, Trio Medicines, and others, are developing novel products to improve the Acne Vulgaris treatment outlook.

• In December 2024, Dermata Therapeutics, Inc. obtained FDA approval for the brand name Xyngari (formerly known as DMT310) for its Phase III acne drug candidate. Approval is contingent upon the successful submission and acceptance of a New Drug Application (NDA).

• In October 2024, Accure Acne, Inc.™ received FDA clearance (K242035) for the treatment of mild to severe inflammatory acne vulgaris.

• In 2023, the US had the largest share of the Acne Vulgaris market among the 7MM, reaching approximately USD 2,949 million, with expectations for further growth by 2034. Across the 7MM, there were around 29,433 thousand diagnosed prevalent cases of acne vulgaris in 2023, a figure that is anticipated to rise during the forecast period (2024-2034). Contributing factors to this increase include hormonal fluctuations, dietary factors, genetic predispositions, and environmental influences like pollution.

• The prevalence of acne vulgaris is categorized by age groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, the 15-19 age group had the highest number of cases, with approximately 5,853 thousand cases in 2023.

• The emerging drug SB204 is expected to launch in the US market by 2027 and could potentially alleviate the disease burden of acne vulgaris in the coming years.

• In 2023, there were approximately 140,217 thousand prevalent cases of Acne Vulgaris across the 7MM, with around 69,500 thousand cases in the US. These figures are expected to rise consistently over the forecast period.

• As per DelveInsight analysis, the Acne Vulgaris market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Acne Vulgaris Market Landscape

Acne Vulgaris Overview

Acne vulgaris is a chronic inflammatory skin condition primarily affecting the pilosebaceous units, with adolescents being the most commonly impacted group. It presents with pimples, blackheads, and whiteheads, and its severity ranges from mild to severe, depending on the presence of non-inflammatory and inflammatory lesions, erythema, and scarring. The condition results from a combination of hormonal changes, excessive sebum production, follicular hyperkeratinization, bacterial growth, and inflammation, influenced by genetics, medications, and environmental factors. Common symptoms include comedones, inflammatory lesions, and scarring.

The growing demand for advanced skincare solutions and non-invasive treatments is driving the acne treatment market. Diagnosis typically involves a clinical examination of the skin, and additional tests such as biopsies, microbial cultures, hormonal evaluations, and liver function tests may be performed to rule out other conditions and better understand the disease.

Do you know the treatment paradigms for different countries? Download our Acne Vulgaris Market Sample Report

Acne Vulgaris Epidemiology Segmentation

DelveInsight’s Acne Vulgaris market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Acne Vulgaris historical patient pools and forecasted Acne Vulgaris patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Acne Vulgaris Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

• Acne Vulgaris Prevalence

• Age-Specific Acne Vulgaris Prevalence

• Gender-Specific Acne Vulgaris Prevalence

• Diagnosed and Treatable Cases of Acne Vulgaris

Visit for more @ Acne Vulgaris Epidemiological Insights

Acne Vulgaris Market Outlook

Effective acne management requires a holistic approach that addresses underlying causes, incorporates lifestyle changes, and includes topical and systemic treatments when necessary. The growing prevalence of acne, increased skincare awareness, and the demand for alternative treatments are driving the current Acne Vulgaris treatment market.

Recent advancements include various topical and systemic therapies targeting different aspects of acne’s complex pathogenesis. Topical treatments like salicylic acid and azelaic acid help improve skin moisture, reduce inflammation, and clear comedones. Severe cases are treated with systemic options such as oral antibiotics (tetracycline, doxycycline), oral retinoids (isotretinoin), and hormonal agents like spironolactone.

Despite existing strategies, current treatments do not fully address the disease burden, highlighting the urgent need for new therapies. The market is eagerly awaiting the launch of promising treatments, including SB204 (Pelthos Therapeutics), DMT310 (Dermata Therapeutics), B244 (AOBiome LLC.), BPX-01 (Timber Pharmaceuticals), and BTX-1503 (Botanix Pharmaceuticals), which could address a critical global public health need if proven effective.

Acne Vulgaris Marketed Drugs

• AKLIEF (Trifarotene)/ CD-5789: Galderma S.A.

• AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc.

• ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics

Acne Vulgaris Emerging Drugs

• SB204: Pelthos Therapeutics

• B244: AOBiome LLC

• DMT310: Dermata Therapeutics

Acne Vulgaris Key Companies

• Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals, and others

For more information, visit Acne Vulgaris Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Acne Vulgaris Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Acne Vulgaris, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Acne Vulgaris epidemiology in the 7MM

• Acne Vulgaris marketed and emerging therapies

• Acne Vulgaris companies

• Acne Vulgaris market drivers and barriers

Table of Contents:

1 Acne Vulgaris Market Key Comprehensive Insights

2 Acne Vulgaris Market Report Introduction

3 Competitive Intelligence Analysis for Acne Vulgaris

4 Acne Vulgaris Market Analysis Overview at a Glance

5 Executive Summary of Acne Vulgaris

6 Acne Vulgaris Epidemiology and Market Methodology

7 Acne Vulgaris Epidemiology and Patient Population

8 Acne Vulgaris Patient Journey

9 Acne Vulgaris Treatment Algorithm, Acne Vulgaris Current Treatment, and Medical Practices

10 Key Endpoints in Acne Vulgaris Clinical Trials

11 Acne Vulgaris Marketed Therapies

12 Acne Vulgaris Emerging Therapies

13 Acne Vulgaris: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Acne Vulgaris

16 Acne Vulgaris Market Key Opinion Leaders Reviews

18 Acne Vulgaris Market Drivers

19 Acne Vulgaris Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Acne Vulgaris Epidemiology 2034

DelveInsight’s “Acne Vulgaris – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Acne Vulgaris epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acne Vulgaris Pipeline 2024

“Acne Vulgaris Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acne Vulgaris market. A detailed picture of the Acne Vulgaris pipeline landscape is provided, which includes the disease overview and Acne Vulgaris treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/